BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 25451942)

  • 1. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
    Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
    J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.
    Al-Zaid B; Chacko S; Ezeamuzie CI; Bünemann M; Krasel C; Karimian T; Lanzerstorfer P; Al-Sabah S
    Pharmacol Res Perspect; 2022 Oct; 10(5):e01013. PubMed ID: 36177761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.
    Roed SN; Wismann P; Underwood CR; Kulahin N; Iversen H; Cappelen KA; Schäffer L; Lehtonen J; Hecksher-Soerensen J; Secher A; Mathiesen JM; Bräuner-Osborne H; Whistler JL; Knudsen SM; Waldhoer M
    Mol Cell Endocrinol; 2014 Feb; 382(2):938-49. PubMed ID: 24275181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
    Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
    Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
    Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
    Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
    J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of glucagon-like peptide-1 receptor and glucose‑dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells.
    Aoyama E; Watari I; Podyma-Inoue KA; Yanagishita M; Ono T
    Int J Mol Med; 2014 Aug; 34(2):475-82. PubMed ID: 24866833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
    PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.
    Folli F; Finzi G; Manfrini R; Galli A; Casiraghi F; Centofanti L; Berra C; Fiorina P; Davalli A; La Rosa S; Perego C; Higgins PB
    Am J Physiol Endocrinol Metab; 2023 Nov; 325(5):E595-E609. PubMed ID: 37729025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
    Zhao F; Zhou Q; Cong Z; Hang K; Zou X; Zhang C; Chen Y; Dai A; Liang A; Ming Q; Wang M; Chen LN; Xu P; Chang R; Feng W; Xia T; Zhang Y; Wu B; Yang D; Zhao L; Xu HE; Wang MW
    Nat Commun; 2022 Feb; 13(1):1057. PubMed ID: 35217653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A; Rosenkilde MM; Gasbjerg LS
    Peptides; 2022 May; 151():170749. PubMed ID: 35065096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes.
    Araki E; Sakaguchi M; Fukuda K; Kondo T
    J Diabetes Investig; 2022 Dec; 13(12):1958-1960. PubMed ID: 36039895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.
    Ali S; Lamont BJ; Charron MJ; Drucker DJ
    J Clin Invest; 2011 May; 121(5):1917-29. PubMed ID: 21540554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and preparation of the class B G protein-coupled receptors GLP-1R and GCGR for
    Wang H; Hu W; Liu D; Wüthrich K
    FEBS J; 2021 Jul; 288(13):4053-4063. PubMed ID: 33369025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R).
    Yang D; de Graaf C; Yang L; Song G; Dai A; Cai X; Feng Y; Reedtz-Runge S; Hanson MA; Yang H; Jiang H; Stevens RC; Wang MW
    J Biol Chem; 2016 Jun; 291(25):12991-3004. PubMed ID: 27059958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
    Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
    Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
    Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
    Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.